SOCIAL INNOVATION
ROUND 1- SOCIAL INNOVATION GENERATION
A. Social buissines idea
A1. Social mantra one-liner
Vascular protection: safeguarding health through disinfection.
A2. Contributions to UN goals
Short-term:
• SDG 3: Good Health and Well-being: The implementation of the device would immediately reduce bloodstream infections, decreasing associated morbidity and mortality. This would lead to an immediate improvement in patients’ health and well-being.
• SDG 6: Clean Water and Sanitation: By reducing nosocomial infections, the device would decrease the need for additional medical treatments, resulting in more efficient use of water resources and a reduction in medical waste generation in the short term.
• SDG 9: Industry, Innovation, and Infrastructure: Introducing the device would represent technological innovation in preventing catheter-related infections, showcasing how technology can enhance safety and efficacy in delivering healthcare services. This would have an immediate impact on healthcare infrastructure.
• SDG 17: Partnerships for the Goals: From the outset, the successful development and implementation of the device would require collaboration from various stakeholders, including manufacturers, healthcare providers, researchers, and governments. These partnerships would be established and strengthened in the short term to effectively address global health challenges.
Long-term:
• SDG 3: Good Health and Well-being: As the implementation of the device is sustained and expanded, a sustained decrease in bloodstream infections could be achieved, leading to continuous improvement in the health and well-being of affected populations.
• SDG 6: Clean Water and Sanitation: With a sustained reduction in nosocomial infections, the burden on water resources would decrease, and long-term medical waste generation would diminish, contributing to a cleaner and more sustainable environment.
• SDG 9: Industry, Innovation, and Infrastructure: Widespread adoption of the device could foster a culture of innovation in healthcare, promoting the development ofnew technologies and practices to address global health challenges. This would lead to significant improvements in healthcare infrastructure and systems in the
• SDG 17: Partnerships for the Goals: Partnerships established during the initial phase of the project would continue to strengthen and expand over time, enabling more effective collaboration in addressing global health challenges sustainably and cohesively.
ESG preparedness
Problem: Bloodstream infections
Justification: Nosocomial bloodstream infections are a significant cause of morbidity and mortality. They can be primary and secondary. The most frequent are primary, related to central venous catheters (CVC), and primarily occur in Intensive Care Units. Secondary infections are related to infections in other sites, such as the lungs, urinary tract, surgical wounds, etc.
Definitions:
IAC encompasses different entities: (i) catheter-associated bacteremia (CAB); (ii) insertion site infection (erythema, induration, increased sensitivity, and/or exudate within 2 cm around the catheter exit site); (iii) tunnel infection (erythema, increased sensitivity, and/or induration more than 2 cm from the exit site along the subcutaneous path of a tunnelized catheter); (iv) pocket infection (erythema and/or induration in the subcutaneous pocket of a totally implantable catheter). In this document, we will address the management of CAB as they are of greater importance in the morbidity and mortality of ICU patients.
It is important to differentiate between the epidemiological definition and the clinical definition of CAB. The epidemiological definition refers to a bloodstream infection (without localized infection) that develops in a patient with a CVC inserted at least 48 hours before the onset of bacteremia (catheter tip culture or retro-culture is not a necessary criterion in this definition). The clinical definition of CAB refers to the finding of at least one positive peripheral blood culture in a patient with clinical signs of infection (fever, chills, and/or hypotension) without another apparent source of bloodstream infection, with a positive catheter tip or retro-culture (with a time differential) with the identical organism and antibiogram. The parameters for identifying the catheter as the source of bacteremia are rigorous and will be described in the Microbiological Diagnosis section of CAB.
At DIPITS, we conduct tests and clinical trials to gain a realistic understanding by interacting with the patient’s hospital environment. This approach allows us to adjust our device with the necessary features to ensure high efficiency. I am sharing evidence of our work, which includes training by medical personnel, customer service by our team, and field practice, demonstrating our role as a collaborative and active organization committed to saving millions of lives.
